Invex Therapeutics Revenue and Competitors

Subiaco, WA USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Invex Therapeutics's estimated annual revenue is currently $620k per year.(i)
  • Invex Therapeutics's estimated revenue per employee is $155,000

Employee Data

  • Invex Therapeutics has 4 Employees.(i)
  • Invex Therapeutics grew their employee count by -43% last year.

Invex Therapeutics's People

NameTitleEmail/Phone
1
Chief Financial Officer & Company SecretaryReveal Email/Phone
2
Contract Clinical Project ManagerReveal Email/Phone
3
Senior Clinical Trials ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.9M60%N/AN/A
#2
$0.9M60%N/AN/A
#3
$3.3M4310%$101MN/A
#4
$5.7M3712%N/AN/A
#5
$7M4541%N/AN/A
#6
$1.7M22-8%N/AN/A
#7
$3.9M504%$10.1MN/A
#8
$1.9M12-73%N/AN/A
#9
$29.3M151-17%$148MN/A
#10
$2M1386%N/AN/A
Add Company

What Is Invex Therapeutics?

Invex Therapeutics (ASX: IXC) is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke and traumatic brain injury. Invex has trademarked its repurposed Exenatide as Presendinâ„¢.

keywords:N/A

N/A

Total Funding

4

Number of Employees

$620k

Revenue (est)

-43%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$0.7M50%N/A
#2
$0.6M50%N/A
#3
$0.6M8-20%N/A
#4
$1M9-10%N/A
#5
$3.5M140%N/A